DE

latest development

London (UK) and Rehovot (Israel) April 24, 2023

Vidac Pharma Holding Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ). (www.vidacpharma.com)

Vidac Pharma Holding Plc. Informs of automatic expiration of a share purchase facility agreement with General Emerging Market (G.E.M) as for April 13th, 2023. As financial Planning of the company did not include Proceeds from this Conditional Agreement it is the opinion of the management that this should not affect company activities.

About Vidac Pharma: Vidac Pharma Holding Plc. London, is the holding company of Vidac Pharma Ltd. Rehovot. The Company is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases.

Disclaimer

The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.

Vidac Pharma Holding PLC

Dr. Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
+972 (0)779300647